The MRI imaging intellectual property of now-defunct contrast developer Epix Pharmaceuticals will be sold in an auction on May 28.
The family of gadolinium-based imaging programs includes Epix's former MS-325 commercial MR angiography imaging agent (currently marketed as Ablavar in the U.S. by Lantheus Medical Imaging of North Billerica, MA). Commercial rights for sale include for Europe, Switzerland, and other regions outside the U.S., Canada, Puerto Rico, and Australia, according to Joseph Finn, founding partner of the Finn, Warnke, and Gayton law firm in Wellesley Hills, MA.
Epix transferred these assets to Finn in July 2009 after the firm said it was shutting down and liquidating its assets. Finn said it is auctioning them off for the benefit of Epix creditors.
The other two programs up for auction include Epix's EP-2104R fibrin-binding MRI agent in phase II clinical development for clot detection, and its EP-3600 collagen-binding MRI agent in preclinical development for myocardial perfusion. Prospective bidders may bid on any combination of the three or all three.
Related Reading
Pharma developer Epix to shut down, liquidate assets, July 23, 2009
Epix to buy shareholders' stock, June 4, 2009
Nasdaq delists Epix stock, May 14, 2009
Epix to pursue strategic alternatives, May 12, 2009
Epix to complete tender offer, May 5, 2009
Copyright © 2010 AuntMinnie.com
.fFmgij6Hin.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
.fFmgij6Hin.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
